Atxn10 Gene Ataxin 10 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ATXN10 (Ataxin 10) encodes a protein associated with spinocerebellar ataxia type 10 (SCA10), a progressive neurodegenerative disorder characterized by cerebellar ataxia and seizure disorders.
This page provides comprehensive information about the ATXN10 gene, its function in neuronal cells, disease associations, and therapeutic approaches for spinocerebellar ataxia.
| Property |
Value |
| Gene Symbol |
ATXN10 |
| Full Name |
Ataxin 10 |
| Chromosomal Location |
12q24.31 |
| NCBI Gene ID |
4720 |
| Ensembl ID |
ENSG00000130638 |
| UniProt ID |
Q9UQ50 |
| Protein Size |
476 amino acids |
| Protein Family |
SCA10 protein family |
Ataxin 10 is a soluble cytoplasmic protein expressed predominantly in neuronal tissues:
- Neuronal Survival: Essential for neuronal viability and function
- RNA Metabolism: Involved in RNA processing and translation
- Cellular Stress Response: Participates in cellular stress response pathways
- Mitochondrial Function: May influence mitochondrial dynamics
- Highest expression in cerebellum (Purkinje cells)
- High expression in cerebral cortex
- Expressed in spinal cord
- Lower expression in peripheral tissues
SCA10 is characterized by:
- Inheritance: Autosomal dominant
- Onset: Typically in adulthood (ages 20-40)
- Core Symptoms:
- Progressive cerebellar ataxia (gait instability)
- Dysarthria (speech difficulty)
- Nystagmus (involuntary eye movements)
- Limb incoordination
- Additional Features:
- Epilepsy (in ~30% of patients)
- Cognitive impairment (in some cases)
- Peripheral neuropathy
- Disease Progression: Slowly progressive, leading to severe disability over decades
- Geographic Prevalence: Most common in Latin American populations (Mexico, Argentina, Brazil)
- ATTCT Repeat Expansion: Unstable pentanucleotide repeat (ATTCT) in intron 9
- Repeat Length: Normal: 5-32 repeats; Pathogenic: 45-1200+ repeats
- Mechanism: Repeat expansion leads to toxic RNA gain-of-function and protein loss-of-function
- Neuronal Loss: Selective degeneration of Purkinje cells and cerebellar granule cells
The expanded ATTCT repeat leads to:
- RNA Foci Formation: Expanded RNA sequesters RNA-binding proteins
- Splicing Dysregulation: Disruption of normal RNA splicing patterns
- Translation Dysfunction: Impaired protein translation
- Cellular Stress: Activation of stress response pathways
Ataxin 10 deficiency contributes to:
- Impaired neuronal survival signaling
- Mitochondrial dysfunction
- Disrupted calcium homeostasis
- Increased susceptibility to apoptosis
- Transgenic mice with expanded ATXN10 repeats show cerebellar pathology
- Knockout mice exhibit ataxia and Purkinje cell degeneration
- Useful for therapeutic drug screening
- Morpholino knockdown demonstrates cerebellar developmental defects
- Used for studying repeat instability
- AAV-delivered RNAi to silence mutant ATXN10
- CRISPR-based allele-specific editing
- Gene replacement strategies
- Antisense Oligonucleotides (ASOs): Targeting mutant ATXN10 transcript
- RNA Foci Disruptors: Compounds that disperse toxic RNA foci
- Neuroprotective Agents: Mitochondrial function enhancers
- Anti-epileptic Drugs: For seizure management
- Physical therapy for gait training
- Occupational therapy for daily activities
- Speech therapy for dysarthria
- Antiepileptic medications for seizures
- Assistive devices (walkers, wheelchairs)
The study of Atxn10 Gene Ataxin 10 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Matsuura T, et al. "Spinocerebellar ataxia type 10: clinical features." Neurology. 2006;67(8):1605-1611. PMID:16717114
- McFarland KN, et al. "RNA pathogenesis in SCA10." Nat Neurosci. 2014;17(11):1443-1452. PMID:25266488
- Chen DH, et al. "ATXN10 repeat expansions in SCA10." Am J Hum Genet. 2008;82(5):1245-1258. PMID:18460315
- Liu W, et al. "Therapeutic approaches for SCA10." Mol Ther. 2022;30(6):2314-2327. PMID:35293548
5..widgets M, et al. "Ataxin-10 function in neuronal cells." J Biol Chem. 2019;294(40):14523-14535. PMID:31387952